Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

American Society of Clinical Oncology (ASCO) - Tập 35 Số 16 - Trang 1795-1802 - 2017
Giovanni Martinelli1, Nicolas Boissel1, Patrice Chevallier1, Oliver G. Ottmann1, Nicola Gökbuget1, Max S. Topp1, Adele K. Fielding1, Alessandro Rambaldi1, Ellen K. Ritchie1, Cristina Papayannidis1, Lulu Ren Sterling1, Jonathan Benjamin1, Anthony S. Stein1
1Giovanni Martinelli and Cristina Papayannidis, Institute of Hematology and Medical Oncology “L. and A. Seràgnoli”, Bologna; Alessandro Rambaldi, University of Milan Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Nicolas Boissel, University Paris Diderot, Hôpital Saint-Louis, Paris; Patrice Chevallier, Centre Hospitalier Universitaire Nantes, Nantes, France; Oliver Ottmann, Cardiff University, Cardiff; Adele K. Fielding, University College London...

Tóm tắt

PurposeFew therapeutic options are available for patients with Philadelphia chromosome–positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of tyrosine kinase inhibitor (TKI) −based therapy. Here, we evaluated the efficacy and tolerability of blinatumomab in patients with relapsed or refractory Ph+ALL.Patients and MethodsThis open-label phase II study enrolled adults with Ph+ALL who had relapsed after or were refractory to at least one second-generation or later TKI or were intolerant to second-generation or later TKIs and intolerant or refractory to imatinib. Blinatumomab was administered in 28-day cycles by continuous intravenous infusion. The primary end point was complete remission (CR) or CR with partial hematologic recovery (CRh) during the first two cycles. Major secondary end points included minimal residual disease response, rate of allogeneic hematopoietic stem-cell transplantation, relapse-free survival, overall survival, and adverse events (AEs).ResultsOf 45 patients, 16 (36%; 95% CI, 22% to 51%) achieved CR/CRh during the first two cycles, including four of 10 patients with the T315I mutation; 88% of CR/CRh responders achieved a complete minimal residual disease response. Seven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (six of 11) of transplantation-naïve responders. Median relapse-free survival and overall survival were 6.7 and 7.1 months, respectively. The most frequent AEs were pyrexia (58%), febrile neutropenia (40%), and headache (31%). Three patients had cytokine release syndrome (all grade 1 or 2), and three patients had grade 3 neurologic events, one of which (aphasia) required temporary treatment interruption. There were no grade 4 or 5 neurologic events.ConclusionSingle-agent blinatumomab showed antileukemia activity in high-risk patients with Ph+ALL who had relapsed or were refractory to TKIs. AEs were consistent with previous experience in Ph–ALL.

Từ khóa


Tài liệu tham khảo

10.1182/asheducation-2011.1.231

10.1016/j.bbmt.2012.08.021

10.1182/blood-2015-02-627935

10.3324/haematol.2014.116954

10.3324/haematol.10822

10.1586/14737140.2014.895669

10.3324/haematol.2015.124016

Lilly MB, 2010, Am J Hematol, 85, 164, 10.1002/ajh.21615

10.1056/NEJMoa1306494

10.1053/beha.2002.0187

10.1182/blood-2012-11-466482

10.1038/sj.leu.2403062

Miller GD, 2014, Biologics, 8, 243

10.1016/j.ccr.2014.07.006

10.1182/blood-2015-08-660977

10.1126/science.1158545

10.1016/S1470-2045(14)71170-2

10.1200/JCO.2014.56.3247

10.1182/blood.V87.12.5213.bloodjournal87125213

National Cancer Institute: NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Bethesda, MD, National Cancer Institute, 2014

10.1016/0197-2456(89)90015-9

10.1182/blood-2011-07-367326

10.1182/blood-2009-01-197186

10.1182/blood-2015-09-666214

10.1038/leu.2012.324

10.1182/blood-2007-02-073528

10.1056/NEJMoa1205127

10.1182/blood.V114.22.644.644

10.1182/blood.V116.21.210.210

10.1056/NEJMoa1509277

10.1007/s11899-015-0248-3

Goldstone AH, 2008, Blood, 111, 1827, 10.1182/blood-2007-10-116582

10.1182/blood-2008-11-185132

10.3324/haematol.10965

10.1038/bcj.2014.48

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 35 Số 16

1795-1802

Thông tin tác giả